Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00408005 · OUTCOME

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent probability
Interval / dispersion
95% Confidence Interval
Time frame
4 years from randomization at the end of induction

What was measured

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event

Analysis population: Includes subjects randomized to Nelarabine versus No Nelarabine

Groups in this outcome

ARM I and ARM III (Combination Chemotherapy)

No Nelarabine (Combined)

ARM II and ARM IV (Combination Chemotherapy)

Nelarabine (Combined)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ARM I and ARM III (Combination Chemotherapy)336
ARM II and ARM IV (Combination Chemotherapy)323

Reported measurements

Source class 1
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARM I and ARM III (Combination Chemotherapy)82.96Not reported78.487.5Not reported
ARM II and ARM IV (Combination Chemotherapy)88.30Not reported84.292.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        78.4
        upper Limit
        87.5
        value
        82.96
      2. group Id
        OG001
        lower Limit
        84.2
        upper Limit
        92.4
        value
        88.30
denoms
  1. counts
    1. group Id
      OG000
      value
      336
    2. group Id
      OG001
      value
      323
    units
    Participants
description
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event
dispersion Type
95% Confidence Interval
groups
  1. description
    No Nelarabine (Combined)
    id
    OG000
    title
    ARM I and ARM III (Combination Chemotherapy)
  2. description
    Nelarabine (Combined)
    id
    OG001
    title
    ARM II and ARM IV (Combination Chemotherapy)
param Type
NUMBER
population Description
Includes subjects randomized to Nelarabine versus No Nelarabine
reporting Status
POSTED
time Frame
4 years from randomization at the end of induction
title
Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
type
PRIMARY
unit Of Measure
percent probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice